Comorbidity as prognostic variable in MDS: Comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS study group

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 114-119

  Sperr, W R ^a   Wimazal, F ^a   Kundi, M ^a   Baumgartner, C ^a   Nosslinger T ^b   Makrai, A ^b   Stauder, R ^c   Krieger, O ^d   Pfeilstocker M ^a,e   Valent, P ^a,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d Hospital of Elisabethinen   (Austria)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Comorbidity; MDS; Prognostication; Survival

Indexed keywords

FERRITIN; LACTATE DEHYDROGENASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; CYTOPENIA; DEMENTIA; DIABETES MELLITUS; DIGESTIVE SYSTEM ULCER; ENTERITIS; EVENT FREE SURVIVAL; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION COMORBIDITY INDEX; HEMIPLEGIA; HUMAN; INFECTION; KARYOTYPE; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OBESITY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RHEUMATIC DISEASE; SCORING SYSTEM; SURVIVAL RATE; TUMOR; VASCULAR DISEASE;

EID: 70449464264     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp258     Document Type: Article

References (40)

1. Boogaerts MA, Verhoef GEG, Demutynk H. Treatment and prognostic factors in myelodysplasic syndromes. Bailliéres Clin Haematol 1996; 9: 161-183.
2. Cole P, Sateren W, Delzell E. Epidemiologic perspectives on myelodysplastic syndromes and leukemia. Leuk Res 1995; 19: 361-365.
3. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998; 83: 358-368.
4. Valent P, Horny HP, Bennett JM et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31(6): 727-736.
5. Germing U, Aul C, Niemeyer CM et al. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008; 87(9): 691-699.
6. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
7. Bennett JM, Catovsky D, Daniel MT et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol 1994; l87: 746-754.
8. Brunning RD, Bennett JM, Flandrin G et al. Myelodysplastic syndromes. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Vol. 1. Lyon, France: IARC Press 2001; 62-73.
9. Brunning RD, Orazi A, Germing U et al. Myelodysplastic syndromes. In Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Vol. 1. Lyon, France: IARC Press 2008; 88-103.
10. Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol 2005; 32: S3-S10.
11. Greenberg PL. Risk factors and their relationship to the prognosis of myelodysplastic syndromes. Leuk Res 1998; 22: S3-S6.
12. Aul C, Gattermann N, Heyll A et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6: 52-59.
13. Aul C, Gattermann N, Germing U et al. Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. Leukemia 1992; 8: 1906-1913.
14. Mufti GJ, Stevens JR, Oseier DG et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1958; 59: 425-433.
15. Sanz GF, Sanz MA, Vallespi T et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes. A multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
16. Morel P, Hebbar M, Lai JL et al. Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system. A report on 408 cases. Leukemia 1993; 7: 1315-1323.
17. Toyama K, Ohyashiki K, Yoshida Y et al. Clinical implications of chromosomal abnormalities in 401 patients with MDS: a multicentric study in Japan. Leukemia 1993; 7: 499-508.
18. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
19. Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
20. Germing U, Strupp C, Kuendgen A et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006; 12: 1596-1604.
21. Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
22. Stauder R, Nösslinger T, Pfeilstöcker M et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw 2008; 9: 927-934.
23. Sorror ML, Sandmaier BM, Storer BE et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246-4254.
24. Etienne A, Esterni B, Charbonnier A et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007; 109: 1376-1383.
25. Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
26. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 109: 2912-2919.
27. Della Porta MG, Kuendgen A, Zipperer E et al. Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. Blood 2008; 112: 925-926.
28. Fonatsch C, Gudat H, Lengfelder E et al. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia 1994; 8: 1318-1326.
29. ISCN (1981). An international system for human cytogenetic nomenclature. Cytogenet Cell Genet 1981; 31: 5-23.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
31. Nimer SD. Myelodysplastic syndromes. Blood 2008; 111: 4841-4851.
32. Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 2005; 10: 258-269.
33. Germing U, Hildebrandt B, Pfeilstöcker M et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223-2231.
34. Stauder R, Wimazal F, Nösslinger T et al. Die individualisierte Riskoeinschä tzung und Therapieplanung bei myelodysplastischen Syndromen. Wien Klin Wochenschr 2008; 120: 523-537.
35. Ahern TP, Lash TL, Thwin SS et al. Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors. Med Care 2009; 47: 73-79.
36. Teppo H, Olli-Pekka Alho OP. Comorbidity and diagnostic delay in cancer of the larynx, tongue and pharynx. Oral Oncol [on-line] 2008; http://dx.doi.org/10.1016/j.oraloncology.2008.10.012.
37. Zafar SY, Abernethy AP, Abbott DH et al. Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. BMC Cancer 2008; 8: 345-353.
38. Tougeron D, Di Fiore F, Thureau S et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 2008; 99: 1586-1592.
39. Thieblemont C, Grossoeuvre A, Houot R et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008; 19: 774-779.
40. Jacot W, Colinet B, Bertrand D et al. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol 2008; 19: 1458-1464.